GlassScriptPhysician profile
Asma H Murad
NPI 1831189604
$2,162.07
in general payments reported to CMS, 2019-2025
23 companies · $485 in 2025
The $485 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $278 · 2021: $298 · 2022: $276 · 2023: $221 · 2024: $383 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,088.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,088.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $449.92 | 2021-2025 | |
| Glaxosmithkline, LLC. | $193.83 | 2020-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $159.29 | 2019-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $138.58 | 2021-2024 | |
| Pfizer INC. | $134.89 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $130.56 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $130.41 | 2021-2024 | Trintellix |
| Esperion Therapeutics, INC. | $114.57 | 2020-2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.84 | 2020-2022 | |
| Amgen INC. | $99.49 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $80.64 | 2019-2025 | |
| Exact Sciences Corporation | $79.50 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Supernus Pharmaceuticals, INC. | $77.21 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $40.50 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $39.06 | 2020-2024 | Airsupra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $31.27 | 2020-2022 | |
| Shield Therapeutics INC | $28.01 | 2023 | Accrufer |
| Inogen, INC. | $24.61 | 2022 | |
| Almatica Pharma LLC | $23.88 | 2025 | Loreev Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.03 | 2025 | Caplyta |
| Abbott Laboratories | $21.81 | 2025 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $20.78 | 2022 | |
| Dexcom, INC. | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asma Murad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.